Molecular structure of WEHI-539, CAS Number: 1431866-33-9
WEHI-539 (CAS 1431866-33-9)
Alternate Names:
WEHI 539 WEHI539 CHEMBL3342187 5-[3-[4-(Aminomethyl)phenoxy]propyl]-2-[(8e)-8-(1,3-Benzothiazol-2-Ylhydrazinylidene)-6,7-Dihydro-5h-Naphthalen-2-Yl]-1,3-Thiazole-4-Carboxylic Acid (E)-5-(3-(4-(aminomethyl)phenoxy)propyl)-2-(8-(2-(benzo[d]thiazol-2-yl)hydrazono)-5,6,7,8-tetrahydronaphthalen-2-yl)thiazole-4-carboxylic acid
CAS Number:
1431866-33-9
Molecular Weight:
583.70
Molecular Formula:
C31H29N5O3S2
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.
QUICK LINKS
Ordering Information
Description
Technical Information
Safety Information
SDS & Certificate of Analysis
WEHI-539 (CAS 1431866-33-9) References
- Structure-guided design of a selective BCL-X(L) inhibitor. | Lessene, G., et al. 2013. Nat Chem Biol. 9: 390-7. PMID: 23603658
- Pharmacological inhibition of Bcl-xL sensitizes osteosarcoma to doxorubicin. | Baranski, Z., et al. 2015. Oncotarget. 6: 36113-25. PMID: 26416351
- Human Pluripotent Stem Cells and Derived Neuroprogenitors Display Differential Degrees of Susceptibility to BH3 Mimetics ABT-263, WEHI-539 and ABT-199. | García, CP., et al. 2016. PLoS One. 11: e0152607. PMID: 27030982
- Antagonism of Bcl-XL is necessary for synergy between carboplatin and BH3 mimetics in ovarian cancer cells. | Abed, MN., et al. 2016. J Ovarian Res. 9: 25. PMID: 27080533
- Selective BCL-XL inhibition promotes apoptosis in combination with MLN8237 in medulloblastoma and pediatric glioblastoma cells. | Levesley, J., et al. 2018. Neuro Oncol. 20: 203-214. PMID: 29016820
- Impact of BH3-mimetics on Human and Mouse Blood Leukocytes: A Comparative Study. | Rohner, L., et al. 2020. Sci Rep. 10: 222. PMID: 31937836
- Epigenetic Targeting of Mcl-1 Is Synthetically Lethal with Bcl-xL/Bcl-2 Inhibition in Model Systems of Glioblastoma. | Shang, E., et al. 2020. Cancers (Basel). 12: PMID: 32752193
- BCL2 inhibitor ABT-199 and BCL2L1 inhibitor WEHI-539 coordinately promote NOXA-mediated degradation of MCL1 in human leukemia cells. | Chiou, JT., et al. 2022. Chem Biol Interact. 361: 109978. PMID: 35561756
- Specific Targeting of Antiapoptotic Bcl-2 Proteins as a Radiosensitizing Approach in Solid Tumors. | Sobol, B., et al. 2022. Int J Mol Sci. 23: PMID: 35887198
- Wnt/β-Catenin Protects Lymphocytes from HIV-Mediated Apoptosis via Induction of Bcl-xL. | Albalawi, YA., et al. 2022. Viruses. 14: PMID: 35891449
Inhibitor of:
Baxα, Bcl-2, Bcl-7c, Bcl-B, Bcl-G, Bcl-w, Bcl-xl, Bclp2, Bfk, Bim EL, CDSN, DNLC2A, GOLT1B, GP2, MOMP, NOXA, and PUMA.Activator of:
Bax, Bcl-B, and Hrk.Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
WEHI-539, 5 mg | sc-507317 | 5 mg | $233.00 |